MESANIC-OD

Description

It works by reducing the amount of acid in the stomach which helps in the relief of acid-related indigestion and ulcers.

Mesalamine is used to treat mild to moderate ulcerative colitis. Mesalamine is also used to prevent the symptoms of ulcerative colitis from recurring.

Common side effects of Mesalamine - Stomach pain/epigastric pain, Flatulence, Headache, Vomiting, Diarrhea, Nausea, Abdominal pain, Rash

Take this medicine exactly as directed by your doctor.Swallow the capsule or tablet whole. Do not open, break, crush, or chew it.

"Although the mechanism of action of mesalazine is not fully understood, it is believed to possess a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Furthermore, mesalazine also has the potential to inhibit the activation of Nuclear Factor kappa B (NFkB) and consequently the production of key pro-inflammatory cytokines. It has been proposed that reduced expression of PPAR gamma nuclear receptors (gamma form of peroxisome proliferator-activated receptors) may be implicated in ulcerative colitis, and that mesalazine produces pharmacodynamic effects through direct activation of PPAR gamma receptors in the colonic/rectal epithelium. Other research also showed the potential involvement of inducible NO synthase (iNOS) and that mesalazine can inhibit this enzyme to amiliorate the enteropathy in inflammatory bowel diseases. Moreover, since increased leukocyte migration, abnormal cytokine production, increased production of arachidonic acid metabolites, particularly leukotriene B4, and increased free radical formation in the inflamed intestinal tissue are all present in patients with inflammatory bowel disease it is also believed that mesalazine has in-vitro and in-vivo pharmacological effects that inhibit leukocyte chemotaxis, decrease cytokine and leukotriene production and scavenge for free radicals.

• 1. Mesalazine may decrease the excretion rate of Abacavir which could result in a higher serum level.


• 2. The risk or severity of bleeding can be increased when Mesalazine is combined with Abciximab.


• 3. Mesalazine may increase the hypoglycemic activities of Acarbose.


• 4. Mesalazine may decrease the antihypertensive activities of Acebutolol.


• 5. The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Aceclofenac.

"You have been prescribed Mesalazine for treating and lowering the symptoms of mild inflammatory bowel disease such as ulcerative colitis. Your doctor may monitor your kidney and liver functions before you start treatment with this medicine and regularly thereafter. Inform your doctor if you have severely decreased kidney or liver function. Do not take Mesalazine if you are allergic to aspirin or if you have blood disorders. Do not stop taking the medication suddenly without talking to your doctor."

If you have missed giving any dose of this medicine, then give it as soon as you remember. If it's already time for the next dose then skip the missed dose and follow the regular dosing schedule. Follow the dosing schedule regularly & take this medicine at regular intervals.

• "1.Mayberry J: The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013 Dec;22(4):375-7. [Article]
• 2. Stolfi C, De Simone V, Pallone F, Monteleone G: Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci. 2013 Sep 3;14(9):17972-85. doi: 10.3390/ijms140917972. [Article]
• 3. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [Article]
• 4. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [Article]
• 5. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18."